Updated: January 18, 2026

Skyrizi Shortage Update: What Patients Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Is Skyrizi in Shortage in 2026?
Why Do Patients Experience Skyrizi Access Problems?
Could Skyrizi Face a True Shortage in the Future?
How to Protect Your Skyrizi Treatment Access
If You Experience an Access Gap, Act Quickly

Is Skyrizi in shortage in 2026? No FDA shortage exists—but access challenges are real. Learn what's driving Skyrizi access problems and what patients can do.

If you've been searching online for "Skyrizi shortage" or "Skyrizi out of stock," you're likely dealing with a real access problem—but the cause may surprise you. Here's the current status of Skyrizi availability in 2026, why access issues happen even without a formal shortage, and what you can do to keep your treatment on track.

Is Skyrizi in Shortage in 2026?

As of 2026, Skyrizi (risankizumab) is not listed on the FDA's Drug Shortages database. The drug is manufactured by AbbVie and is available through specialty pharmacy networks across the United States. Unlike medications such as GLP-1 agonists or ADHD stimulants that have faced true supply-chain shortages in recent years, Skyrizi's manufacturing and distribution appear stable.

However, "not in shortage" does not mean "easy to access." A significant number of patients experience real barriers to obtaining Skyrizi—and understanding those barriers is key to solving the problem.

Why Do Patients Experience Skyrizi Access Problems?

Skyrizi access issues are driven by a complex combination of administrative and financial barriers:

Prior authorization (PA) requirements: Virtually every insurance plan requires PA before covering Skyrizi. With list prices around $22,000 per dose, insurers apply rigorous review processes that can take weeks.

Step therapy requirements: Many plans require patients to fail a TNF inhibitor (like Humira) before approving Skyrizi—sometimes adding months of delay.

Specialty pharmacy-only distribution: Skyrizi is not dispensed at retail pharmacies. It requires a specialty pharmacy that has a contract with your insurer, adding a logistical layer to every refill.

Insurance denials and appeals: First-time PA denials are common with specialty biologics. Navigating internal and external appeals can extend treatment delays by weeks or months.

PA renewal lapses: Most insurers require PA renewal every 6–12 months. Patients who miss the renewal window may experience a gap in coverage and an interruption in their Skyrizi supply.

Could Skyrizi Face a True Shortage in the Future?

While there is no current Skyrizi shortage, biologic medications can face supply disruptions under certain conditions—manufacturing issues, unexpected demand surges, or distribution disruptions. Skyrizi has seen rapid demand growth as AbbVie has expanded its indications from plaque psoriasis (2019) to psoriatic arthritis (2022), Crohn's disease (2022), and ulcerative colitis. As patient populations grow and international approvals expand, demand pressure on manufacturing could theoretically emerge.

To date, AbbVie has not indicated any anticipated supply concerns with Skyrizi. The drug is manufactured at multiple AbbVie facilities.

How to Protect Your Skyrizi Treatment Access

Given that administrative barriers are the primary access threat for Skyrizi patients, proactive management is your best protection. Here's what to do:

Renew your PA on time. Start the renewal process at least 30 days before your current authorization expires to prevent any gap in coverage.

Stay enrolled in Skyrizi Complete. AbbVie's Skyrizi Complete provides a Nurse Ambassador, insurance tracking, and a bridge program (no-cost medication for eligible patients during insurance delays). Call 1-866-SKYRIZI to enroll.

Keep records of prior treatment history. Maintain documentation of all prior biologics and conventional therapies tried, including dates, dosages, and reasons for discontinuation. This makes PA renewals and appeals faster.

Monitor your specialty pharmacy refill schedule. Contact your specialty pharmacy 2 weeks before your dose is due to confirm the refill is scheduled and PA is current.

If You Experience an Access Gap, Act Quickly

If your Skyrizi prescription is delayed due to insurance, PA lapse, or specialty pharmacy issues, medfinder can help you quickly locate which pharmacies can fill your prescription while you resolve the administrative issue. Contact Skyrizi Complete, your prescriber's office, and your insurance company simultaneously to reduce delays as much as possible.

If the access gap is prolonged, speak with your specialist about bridge therapy options. See our guide on Alternatives to Skyrizi If You Can't Fill Your Prescription for a breakdown of what other treatments are available.

Frequently Asked Questions

No. As of 2026, Skyrizi (risankizumab) is not listed on the FDA Drug Shortages database. AbbVie manufactures Skyrizi at multiple facilities, and distribution through specialty pharmacy networks remains stable. Access challenges patients face are primarily administrative—related to prior authorization, step therapy requirements, and specialty pharmacy logistics—not a physical drug shortage.

Skyrizi is a high-cost specialty biologic with a list price of approximately $22,000 per dose, which triggers extensive insurance oversight. Almost every payer requires prior authorization, step therapy documentation, and specialty pharmacy dispensing. These administrative requirements can create weeks or months of delay even when the drug itself is available. Additionally, PA renewals are required every 6–12 months and lapses can interrupt treatment.

If your Skyrizi shipment is delayed, contact your specialty pharmacy immediately to check the status, verify your prior authorization is current and hasn't expired, and call the Skyrizi Complete support line at 1-866-SKYRIZI. If a delay is related to insurance approval, AbbVie's bridge program may provide Skyrizi at no charge to eligible commercially insured patients while the issue is resolved.

For Skyrizi maintenance doses (every 8–12 weeks depending on your condition), contact your specialty pharmacy at least 2 weeks before your scheduled dose date to confirm the refill is on track and that your prior authorization is still current. If your PA is approaching expiration, initiate renewal at least 30 days early to avoid any treatment gap.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards